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Abstract
Although nonsuicidal self-injury (NSSI) is a clinically significant behavior, evidence-based, specific, time-, and cost-effective 
treatment approaches are lacking. The aim of this study was to compare the efficacies of a brief cognitive-behavioral psycho-
therapy manual, the Cutting Down Programme (CDP), and treatment as usual (TAU) in the treatment of adolescent NSSI. 
We conducted a single-centre randomised controlled trial (RCT). Eligible participants were aged 12–17 years engaging in 
repetitive NSSI (at least 5 times within the past 6 months). We randomly allocated 74 participants to CDP (n = 37) or TAU 
(n = 37; in a 1:1 ratio). Outcome measures were administered before treatment (T0), directly after CDP or 4 months after 
baseline evaluation in the TAU group (T1), and another 6 months later (T2; primary endpoint). Primary outcome was a 50% 
reduction in NSSI frequency within the past 6 months at 10-month follow-up (T2). Regarding the primary outcome, there 
were no significant differences between the CDP (n = 26; 70.3%) and TAU group [n = 27; 73.0%; χ2(1) = 0.07; p = 0.797]; 
NSSI frequency within the past 6 months was significantly reduced at T2 [χ2(1) = 12.45; p < 0.001] with no between-group 
difference [χ2(1) = 0.14; p = 0.704]. However, we found a significant group x point of measurement interaction [χ2(2) = 7.78; 
p = 0.021] regarding NSSI within the last month indicating at T1. CDP was equally effective and achieved faster recovery 
compared to a significantly more intensive TAU in treating adolescent NSSI. The CDP could provide a brief and pragmatic 
first treatment within a stepped-care model for NSSI in routine clinical care.
Clinical Trial Registration The trial was prospectively registered in the German Registry of Clinical Trials (https ://www.
drks.de; DRKS00003605) and is now complete.
Keywords Nonsuicidal self-injury · Randomised controlled trial · Adolescents · Psychotherapy
Introduction
Nonsuicidal self-injury (NSSI) is defined “as the deliber-
ate, self-inflicted damage of body tissue without suicidal 
intent and for purposes not socially or culturally sanctioned” 
(International Society for the Study of Self-Injury, ISSS). 
Electronic supplementary material The online version of this 
article (https ://doi.org/10.1007/s0078 7-019-01399 -1) contains 
supplementary material, which is available to authorized users.
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According to a large systematic review, approximately 
17–18% of adolescents worldwide report at least a single 
episode of NSSI during lifetime [1]. NSSI is associated with 
a variety of psychiatric disorders and an elevated risk of 
suicidal behavior [2]
To date, there is no universally agreed best practice 
for the treatment of NSSI [3]. A recent systematic review 
revealed that there are effective treatments, which include or 
can be expanded to include the treatment of NSSI. However, 
these approaches were mostly neither developed for nor do 
they specifically focus on NSSI [4]. Particularly, in the con-
text of (emerging) borderline personality disorder (BPD), 
NSSI is often treated with dialectical behavior therapy 
for adolescents (DBT-A), which was found to be effective 
within a randomised controlled trial (RCT) [5]. These treat-
ment effects remained stable within an 1-year follow-up [6]. 
Other treatments that seem effective are mentalization-based 
treatment for adolescents (MBT-A) and cognitive-behavioral 
therapy (CBT) [3, 7].
The need for our trial is illustrated on the example of 
DBT-A: one of the first aims within the DBT-A target hierar-
chy is the elimination of severe NSSI. In further stages, how-
ever, DBT-A targets a broad spectrum of BPD symptoms 
beyond NSSI. Therefore, this approach is rather extensive. 
In addition, DBT-A requires intensive additional training 
for therapists. Hence, access to this treatment approach is 
restricted due to limited resources and a shortage of well-
trained clinicians [8]. Considering the lack of such spe-
cialized treatments available as well as the transdiagnostic 
character of NSSI [9], less intensive and easy accessible 
treatments that address NSSI beyond BPD are essential. 
Such specific treatment approaches may improve the general 
standard of care, especially for adolescents who are often 
struggling to receive adequate professional help [10].
A randomised controlled pilot study investigated the 
effectiveness of a brief behavioral intervention for NSSI 
in young adults (Treatment for Self-injurious Behaviors, 
T-SIB) [11]. It was found that T-SIB was moderately effec-
tive for decreasing NSSI [11]. However, the study only 
enrolled a small number of participants, and did not focus 
on the critical period of adolescence [12].
In 1999, a cognitive-oriented and problem-focused short-
term psychotherapy was developed for adults exhibiting non-
suicidal as well as suicidal self-injury [manual-assisted cog-
nitive-behavior therapy (MACT)] [13]. Thus, it is important 
to note that this approach did not focus specifically on NSSI, 
such as T-SIB, but in addition on suicidal self-injury (SSI). 
Within a first RCT (n = 34), the subjects in the MACT group 
(n = 18) had a significantly greater reduction in the frequen-
cies of self-harm incidents, suicide attempts and depressive 
symptoms compared to the treatment as usual (TAU) group 
(n = 16) [13]. However, within another large RCT (n = 480), 
there were no significant differences to a TAU, so that the 
use of the MACT was not supported in the routine treatment 
of patients [14].
In 2011, the MACT was adapted for adolescents in “The 
Cutting Down Programme” (CDP). A pilot study investi-
gated 25 adolescents aged 12–18 years and provided prelimi-
nary evidence that the CDP may be efficacious in reducing 
NSSI, suicidality, comorbid depression, and trait anxiety 
[15]. Overall, 16 (64%) participants completed the inter-
vention with an average number of only 8.5 sessions in this 
study. Outcomes were assessed at baseline, at the end of the 
treatment and at a follow-up after 3 months. Another impor-
tant result was that the intervention was highly acceptable to 
patients and therapists. However, the sample size was rather 
small and the study did not employ a randomized controlled 
design [15].
In the present study, we tested the efficacy of the CDP 
compared to a more intensive TAU within a RCT. Our pri-
mary hypothesis was that significantly more adolescents in 
the CDP group would exhibit clinically significant reduc-
tions (at least 50%) in the frequency of NSSI within the last 
6 months at follow-up (T2) than those in the TAU group. 
Primary outcome was a 50% reduction in the frequency of 
NSSI within the last 6 months at T2.
Methods
Study design
The present monocentric RCT aimed to compare CDP with 
TAU of higher treatment intensity. Figure 1 illustrates the 
study design, and Fig. 2 contains the trial profile. The RCT 
was conducted at the outpatient clinic for Adolescent Risk-
taking and Self-harm behavior (AtR!Sk) at the Clinic of 
Child and Adolescent Psychiatry at the University Hospital 
Heidelberg, Germany. The authors assert that all procedures 
contributing to this work comply with the ethical standards 
of the relevant national and institutional committees on 
human experimentation and with the Declaration of Hel-
sinki. All procedures involving human subjects/patients were 
approved by the institutional review board of the medical 
faculty at the University of Heidelberg (Ethics Committee 
Fig. 1  Study design
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No.: S-363/2011). The study design and procedures are pre-
sented in full in the published study protocol [16]. The trial 
was conducted and reported in accordance with CONSORT 
guidelines.
Participant recruitment
Participants were recruited via our in- and outpatient units, 
or using official notices, newspaper articles, advertisements, 
and study flyers. The eligible participants were between 12 
and 17 years, and they were required to have engaged in 
NSSI at least 5 days during the previous 6 months and at 
least once during the past month. Exclusion criteria were 
acute psychotic symptoms, acute intent to harm self or 
others that requires intensive psychiatric inpatient treatment, 
impaired intellectual functioning, and/or currently receiving 
psychotherapeutic treatment. Eligibility was established by 
a clinical psychologist during a telephone screening, and 
if adolescents were suitable, written informed consent was 
appropriately obtained from all participants and caregivers 
(if participants were below 16 years of age) either via mail 
or during an information appointment. Subsequently, partici-
pants were invited to attend a baseline assessment.
Assessments
Participants were assessed at three timepoints: baseline 
(before randomisation, T0); after the completion of the 
Fig. 2  Trial profile
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CDP or 4 months after T0 within the TAU group to match 
the assessment points (T1); follow-up assessments (T2) 
6 months after T1 (Fig. 2). To arrange for the T1 and T2 
assessments, participants were contacted via phone. Par-
ticipants received financial reimbursement following each 
assessment (T0–T2). All data were collected on paper forms 
and scanned for automatic data entry. Inconsistencies were 
resolved by checking the original paper material.
Outcomes
The primary outcome was a 50% reduction of NSSI fre-
quency within the past 6 months at T2, via the German ver-
sion of the Self-Injurious Thoughts and Behaviors Interview 
(SITBI-G) [17, 18]. This interview has been validated in 
adolescents (12–19 years) [17] and is considered reliable 
(κs = 0.77–1.00) [18]. The choice to use a 50% reduction in 
NSSI as an indicator of efficacy was made, because it is a 
clinical relevant outcome. This procedure is derived from the 
approach of Jacobson and Truax [19] which relates to sup-
plementary information, namely, clinically relevant infor-
mation over and above the information available from test 
statistics [20].
The secondary outcomes were a 50% reduction of NSSI 
within the past month, changes in NSSI frequency over 
time (within the last month and the last 6 months), suicide 
attempts within the last 6 months, depressive symptoms, 
and quality of life. NSSI and suicide attempts were assessed 
at every timepoint (T0–T2) using the SITBI-G. The Ger-
man version of the Beck-Depression-Inventory-II (BDI-II) 
[21] was used to assess depressive symptoms at T0, T1, 
and T2. The BDI-II is considered reliable (r = 0.93) [21], 
and adequate for the use in adolescent samples [22]. The 
KIDSCREEN-27 questionnaire for children and adolescents 
(8–18 years of age) was used to assess subjective health 
and well-being at T0, T1, and T2. This version shows good 
internal consistency (α = 0.70) [23].
Baseline assessment measures were comorbid mental 
disorders, which were assessed at T0 using the German ver-
sion of the Mini-International Neuropsychiatric Interview 
for children and adolescents aged 6–17 years (M.I.N.I.-KID 
6.0) [24, 25] and parts of the Structured Clinical Interview 
for DSM-IV-Axis II (SCID-II) [26]. In the present study, 
criteria for avoidant, dependent, borderline, and antisocial 
personality disorders were assessed. The M.I.N.I.-KID is a 
valid and reliable measure (κs = 0.64–1.00) [24]. Although 
the SCID-II has been validated in adults [26], it is suitable 
for the use in adolescents [27] and reliable (κs = 0.77–0.94) 
[28].
Within AtR!Sk, assessors underwent specific training 
and regular reliability checks. To check for inter-rater reli-
ability, audiotaped interviews of each clinician, consisting 
of the M.I.N.I.-Kid [24], the SCID II (borderline, avoidant, 
dependent, and antisocial personality disorder) [26], as 
well as the SITBI-G [17] were recorded. Interviews were 
assessed by independent second raters blind for the first 
raters’ scores and diagnoses. Concerning the SITBI-G very 
good-to-perfect agreements were found within the inter-
rater reliability checks (κs = 0.77–1.00) [18]. Regarding the 
SCID II, diagnostic agreement for full-threshold BPD was 
at 93.6% [29]. The clinician responsible for the interviews 
within the present study was involved in all inter-rater reli-
ability checks mentioned in this section.
Randomisation and masking
Participants were randomised after completing the baseline 
assessment (T0). They were randomly assigned (in a 1:1 
ratio) to receive either CDP or TAU using baseline adaptive 
randomisation. The probability of assignment to the CDP 
group was set to the proportion of designated CDP partici-
pants in the not yet randomized participants. This prevents 
large differences in group size during the time of the study 
and reduces the influence of seasonal effects. The randomi-
sation was conducted by a researcher who was not involved 
in the diagnostic or treatment procedures using pseudoran-
dom numbers generated by Stata 12. The seed for the pseu-
dorandom numbers was set to the time of day in seconds at 
the start of the randomisation. Allocation was undertaken 
using a password-protected website, independent of the 
trial. An independent staff member informed participants 
of the outcome of randomisation via telephone. All study 
assessments were performed by the same experienced and 
specially trained clinical psychologist at our clinic who was 
blinded to the participant’s group allocation for the dura-
tion of the follow-up period using a separate and encrypted 
patient list. When asked after completion of interviews 
which treatment the assessor thought each patient received 
initially, the assessor’s responses were correct for 49.1% of 
participants, indicating that masking was successful. Patients 
and clinicians were aware of treatment allocation.
Treatment as usual
The participants in the TAU group were referred to local 
cooperating child and adolescent psychotherapists and psy-
chiatrists either in private practice or in psychotherapeutic 
institutes. All participating therapists and institutes commit-
ted themselves to providing the first appointment and subse-
quent psychotherapeutic treatments within 2–4 weeks after 
baseline assessment. Psychotherapeutic approaches included 
either CBT or psychodynamic oriented psychotherapy. Most 
of the participants received CBT (n = 28, 75.7%; see Fig. 2). 
For detailed information on the TAU see Supplement 1.
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Cutting Down Programme
The manualized CDP that was applied in this study was 
based on elements of CBT and DBT and specifically tailored 
to the treatment of NSSI in adolescents. The treatment length 
was eight to 12 sessions. The manual organized the treat-
ment into four modules that could be expanded with optional 
modules. Module 1 focused on promoting therapy motiva-
tion. The focus of module 2 was on identifying reasons for 
NSSI. In module 3, patients tested alternative behaviors to 
NSSI, and module 4 comprised stabilization of alternative 
behaviors [16]. The sessions were held once a week usually 
over a time of 2–4 months. Parental involvement was not 
specifically intended; however, appointments with parents 
were possible as needed. This decision was made by the 
therapist. Five therapists delivered 37 individual CDP thera-
pies within our specialized outpatient clinic (AtR!Sk). For 
detailed information on the CDP see Supplement 2.
Study therapists were clinical psychologists (Master 
in clinical psychology) who were in training in CBT to 
become licensed psychotherapists. They already completed 
their intermediate exams after 1.5 years. In the context of 
the present study, they were trained in the CDP manual. 
Training consisted of two different aspects: in addition to 
the CDP treatment manual, there was a separate training 
manual to provide study therapists with detailed instructions 
and guidelines about the conduct of the treatment. Beyond 
that, an experienced clinical psychologist, who translated the 
manual, explicated the CDP training and treatment manual 
within a brief additional training session.
To measure adherence to the treatment manual, we used 
observational methods in terms of video recording and indi-
rect measures. Video-based analyses of recorded therapy 
sessions were performed within supervision. An external 
supervisor, who was not involved in the study, checked the 
presented videos for adherence to the CDP manual. Types 
of rating were: occurrence of specific interventions (yes/
no) and frequency counts (how often an intervention occurs, 
expressed numerically). This was done once in a month. In 
addition, indirect adherence measures were used. Thus, the 
study therapists documented the specific exercises of each 
module as well as the corresponding work sheets in stand-
ardized psychotherapy notes, which were checked once a 
week by an independent staff member.
Statistical analysis
All analyses were intent-to-treat analyses (ITT). The study 
was powered to compare the effectiveness of the CDP and 
TAU in the treatment of NSSI. In secondary analyses, we 
used frequencies of NSSI in addition. We expected the 
CDP to result in greater reductions in NSSI incidents with 
a response rate difference of 35% (e.g. CDP: 60%; TAU: 
25%). A response rate difference of 0.35 was considered to 
be clinically important. Similar rate differences were used 
within the power calculation of another RCT investigating 
CBT in patients with BPD [30]. To detect a rate difference 
of 0.35 with a power of 0.85 (α = 0.05), 35 participants were 
needed in each group.
Descriptive analyses were used to characterize the base-
line study sample. Nominal data are presented as frequen-
cies, while continuous data are presented as mean and 
standard deviation (SD) with confidence intervals. For vari-
ables with highly askew distribution, data are presented as 
medians and interquartile ranges. The influence of potential 
confounding variables was analyzed calculating regression 
models with and without covariates that were then compared 
using likelihood-ratio tests.
For our primary outcome, the TAU and CDP groups 
were compared with χ2 tests. Secondary outcomes were 
analyzed as follows. The changes in NSSI as well as in sui-
cide attempts over time were analyzed with mixed-effects 
negative binomial regression because of the overdispersion 
of rates. In addition, to account for zero-inflation in sui-
cide attempts, a zero-inflated negative binomial regression 
was calculated. To analyze a 50% reduction in NSSI within 
the last month, both groups were compared with χ2 tests. 
Changes in depressive symptoms and quality of life over 
time were analyzed with mixed-effects multi-level regres-
sion. All analyses were performed with Stata (version 14; 
Stata Corp LLC, College Station, TX, USA).
Data were monitored by an independent researcher who 
was not involved in the study procedures. The trial was pro-
spectively registered in the German Registry of Clinical 
Trials (https ://www.drks.de; DRKS00003605) and is now 
complete.
Role of the funding source
The funder of the study had no role in study design, data col-
lection, data analysis, data interpretation, or writing of the 
report. The corresponding author had full access to all the 
data in the study and had final responsibility for the decision 
to submit for publication.
Results
Between July 1, 2012, and February 1, 2016, of 96 partici-
pants assessed for eligibility, we recruited 74 participants. 
Of these, 37 participants were allocated to receive CDP 
and 37 participants were allocated to receive TAU (Fig. 2). 
Primary and secondary outcome data were obtained for 37 
(100%) participants in the CDP and 37 (100%) participants 
in the TAU group. We retained 74 (100%) of 74 participants 
over the 10-month follow-up period.
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Baseline characteristics were balanced between the two 
groups (Table 1).
Table 2 shows the number of completed therapy ses-
sions as well as rates of supporting medication. The TAU 
group completed more therapeutic sessions on average 
than the CDP group did (p = 0.021), which indicates 
higher treatment intensity in the TAU group as expected. 
Concerning medication, there were no differences between 
the groups.
Analysis of the primary outcome showed that the majority 
of participants in both groups reached a 50% reduction in 
NSSI (TAU: n = 27; 73.0% vs. CDP: n = 26; 70.3%). Con-
trary to our hypothesis, there was no difference between the 
two groups [χ2(1) = 0.07; p = 0.797].
50% NSSI reduction within the last month Within the 
CDP group, significantly more participants (n = 28; 75.0%) 
exhibited reductions of at least 50% in the frequency of NSSI 
within the last month at T1 [χ2(1) = 4.25; p = 0.039] than the 
Table 1  Sociodemographic and 
clinical sample characteristics 
at T0
SD standard deviation
a Foerderschule: school for students with special needs; Hauptschule: nine years of elementary school; 
Realschule: six years of school after four years of elementary school, terminating with a secondary school 
level-I certificate; Gymnasium: eight years of school after four years of elementary school, terminating 
with the general qualification for university entrance
b Multiple diagnoses per subject possible
Sociodemographic variable/diagnostic category TAU (N = 37) CDP (N = 37) Total 
(N = 74)
Age M SD M SD M SD
15.2 1.1 14.6 1.3 14.9 1.2
Sex N % N % N %
 Female 34 91.9 37 100.0 71 96.0
 Male 3 8.1 0 0.0 3 4.1
School  typea N % N % N %
 Hauptschule/foerderschule 3 8.1 8 21.6 11 14.9
 Realschule 13 35.1 17 46.0 30 40.5
 Gymnasium 21 56.8 12 32.4 33 44.6
Migration status N % N % N %
 Kazakhstan 0 0.0 1 2.7 1 1.4
 India 0 0.0 1 2.7 1 1.4
 Russia 0 0.0 1 2.7 1 1.4
 Spain 0 0.0 1 2.7 1 1·4
 Portugal 1 2.7 0 0.0 1 1.4
 Denmark 1 2.7 0 0.0 1 1.4
 Germany 35 94.6 33 89.2 68 91.9
M.I.N.I.-Kid primary  diagnosesb N % N % N %
 No diagnosis 2 5.4 1 2.7 3 4.1
 Current major depression 16 43.2 11 29.7 27 36.5
 Past major depression 2 5.4 1 2.7 3 4.1
 Recurrent depressive disorder 2 5.4 6 16.2 8 10.8
 Dysthymia 9 24.3 7 18.9 16 21.6
 Agoraphobia 1 2.7 0 0.0 1 1.4
 Social phobias 1 2.7 1 2.7 2 2.7
 Post-traumatic stress disorder 1 2.7 1 2.7 2 2.7
 Drug/alcohol dependence 0 0.0 1 2.7 1 1.4
 ADHD 1 2.7 0 0.0 1 1.4
 Oppositional defiant disorder 0 0.0 3 8.1 3 4.1
 Affective disorders with psychotic features 0 0.0 1 2.7 1 1.4
 Bulimia nervosa 0 0.0 1 2.7 1 1.4
 Adjustment disorders 2 5.4 3 8.1 5 6.8
SCID-II
 Borderline personality disorder 8 21.6 15 40.5 23 31.1
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participants in the TAU group did (n = 19; 51.4%). At T2, 
the difference between the groups was no longer significant 
[χ2(1) = 2.09; p = 0.148].
NSSI frequencies within the last month and the last 
6 months Medians and interquartile ranges are shown in 
Table 2. Although both groups exhibited significant reduc-
tions in the frequency of NSSI incidents within the previous 
6 months [χ2(1) = 12.45; p < 0.001], reductions did not differ 
significantly between the groups [χ2(1) = 0.14; p = 0.704]. 
Both groups also exhibited significant reductions in the 
NSSI frequencies within the last month [χ2(2) = 53.54; 
p < 0.001; see Fig. 3]. In addition, we found a significant 
group × point of measurement interaction [χ2(2) = 7.78; 
p = 0.021] regarding NSSI incidents within the last month. 
Thus, the CDP group exhibited a faster reduction in the fre-
quency of NSSI incidents compared with the TAU group. 
This group × point of measurement interaction remained 
stable when controlling for the number of therapy sessions 
[χ2(2) = 8.77; p = 0.012].
Effect sizes for the reduction of NSSI frequency were 
large in both groups (TAU: Cohen’s d = 0.79; CDP: Cohen’s 
d = 0.99).
Table 2  Participation in 
intervention programs and 
effects on clinical outcomes
IQR interquartile ranges
a Group differences regarding primary and secondary outcome criteria
Intervention/clinical outcome TAU CDP Group differences
Treatment adherence M SD M SD p valuea
 Mean number of sessions attended to T1 5.0 4.3 9.6 2.7 < 0.001
 Mean number of sessions attended to T2 14.3 13.0 3.3 6.5 < 0.001
 Total mean number of sessions attended 19.3 14.0 12.9 7.9 0.021
Medication (subjects) N N P value
 T1 0.693
  Antidepressants 2 1
  Neuroleptics – –
  Methylphenidate – 1
 T2 0.258
  Antidepressants 4 4
  Neuroleptics – 1
  Methylphenidate – 2
NSSI in last 6 months Median IQR Median IQR p value
0.461
 T0 60 30–95 50 25–90
 T2 8 1–50 10 2–40
NSSI in last month Median IQR Median IQR p value
0.565
 T0 4 1–13 10 4–15
 T1 1 0–10 1 0–3
 T2 1 0–2 0 0–2
Suicide attempts in last 6 months M SD M SD p value
0.353
 T0 0.4 0.8 0.5 0.8
 T2 0.3 0.7 0.1 0.4
BDI-II scores M SD M SD p value
0.980
 T0 32.7 10.2 32.9 11.7
 T1 27.1 12.4 25.1 15.0
 T2 20.9 14.9 22.8 13.9
KIDSCREEN-27 M SD M SD p value
0.774
 T0 38.1 5.4 39.0 7.0
 T1 41.0 6.2 42.6 7.5
 T2 44.7 8.4 43.7 8.9
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Attempted suicides within the last 6 months As shown 
in Table 2 and Fig. 3, both groups demonstrated decreased 
attempted suicides within the last 6  months over time 
[χ2(2) = 6.76; p = 0.034], with no significant difference 
between the treatment groups [χ2(1) = 0.86; p = 0.353]. 
This was also true when accounting for zero-inflation (Coef. 
− 0.57, 95% CI − 1.43 to 0.29, p = 0.195).
Depressive symptoms At T0, both groups were severely 
depressed (Table 2). As shown in Fig. 3, both the TAU and 
CDP groups reported significant reductions in depression 
over time [TAU: T0: 32.7; T1: 27.1; T2: 20.9; CDP: T0: 
32.9; T1: 25.1; T2: 22.8; χ2(2) = 55.62; p < 0.001] with again 
no group difference [χ2(1) = 0.00; p = 0.980].
Quality of life The T0 assessment using the KID-
SCREEN-27 showed that both groups had similar levels 
of well-being. As shown in Fig. 3 and Table 2, quality 
of life increased significantly for both groups over time 
[χ2(2) = 43.70; p < 0.001], without any group differences 
[χ2(1) = 0.08; p = 0.774].
There were no adverse events related to the interventions 
of the trial.
To control for potential confounding variables, we took 
treatment dose, BPD as well as depression as covariates 
within separate regression models into account, and com-
pared them with the respective models without covariates. In 
general, models including covariates predicting the primary 
outcome did not differ from those without covariates (treat-
ment dose: p = 0.851; BPD: p = 0.095; depression (BDI-II): 
p = 0.524). The same applied to the regression models that 
included the significant group × point of measurement inter-
action regarding NSSI incidents within the last month [treat-
ment dose: p = 0.312; BPD: p = 0.407; depression (BDI-II): 
p = 0.142]. For further information on analyses of confound-
ing variables see Supplement 3.
Discussion
At T2, there was no evidence for the superiority of CDP 
compared with a significantly more intensive TAU for ado-
lescents with repetitive NSSI. This was true for the primary 
outcome of a 50% reduction in NSSI frequency within the 
Fig. 3  Secondary outcomes: change of NSSI frequencies within the last month, suicide attempts, quality of life, and depression
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past 6 months as well as any of the secondary outcomes. 
Before this study, no study had compared the CDP with 
TAU.
Within a prior RCT with a 6-month follow-up, the adult 
version of the CDP, the MACT (n = 18), was compared to 
TAU (n = 16) and resulted in lower relapse rates regard-
ing suicidal acts (56% for MACT vs. 71% for TAU) [13]. 
Beyond that, the CDP was investigated within a pilot study 
among 25 adolescents with repetitive NSSI. Results sug-
gested preliminary evidence that the CDP may reduce NSSI, 
depression and trait anxiety [15].
The present findings showed that outpatient treatment 
with either CDP or TAU significantly and equally decreased 
NSSI, suicide attempts, and depression symptoms as well as 
significantly increased quality of life with large effect sizes 
at T2. These results are consistent with data showing that 
psychotherapeutic interventions are effective for treating 
NSSI [3]. T1 assessments, however, showed that the CDP 
group exhibited faster reductions in the frequency of NSSI 
within the last month. Results in the CDP group remained 
stable at T2 suggesting that the effects on NSSI endure even 
after termination of a brief intervention.
In our study, CDP patients received a significantly lower 
treatment dose (i.e., psychotherapy sessions) compared to 
the TAU patients. However, there was no effect of treatment 
dose on outcomes indicating that successful treatment of 
NSSI can be ensured using a brief psychotherapeutic inter-
vention. Comparing our trial with previous studies, patients 
treated with MBT-A and DBT-A during previous RCTs 
had also completed significantly more therapeutic sessions 
compared to CDP patients who only completed a mean of 
10 sessions [6, 7]. In addition, the TAU groups examined 
in other RCTs of NSSI provided a similar number of ses-
sions compared to the respective index group [5, 7]. Our and 
other TAU groups were clinical samples with comparable 
group sizes [5, 7]. Regarding outcomes, however, the effect 
sizes for the reduction in the frequency of NSSI in previous 
TAU groups were rather small in the other RCTs (Cohen’s 
d between 0.23 and 0.40) [5, 7] compared to the large effect 
sizes found in the present study (Cohen’s d = 0.79). Finally, 
trials on both MBT-A and DBT-A revealed no superiority 
regarding celerity of NSSI reduction compared to the TAU 
groups [6, 7].
This RCT has high ecological validity concerning the 
majority of patients engaging in NSSI. Since NSSI can occur 
in the context of various disorders [12] and is commonly 
associated with suicidality [2], we did not exclude patients 
based on comorbid disorders or suicidality (except acute 
symptoms that prohibited outpatient treatment). Secondary 
analyses indicated that treatment effects were independent 
of major comorbid disorders [e.g., BPD or major depressive 
disorder (MDD)]. Thus, the CDP seems effective for treat-
ing NSSI in the context of a broad spectrum of comorbid 
diagnoses. Furthermore, our study focused on mid-ado-
lescence, during which NSSI prevalence rates peak, while 
help-seeking is commonly low [10]. The internal validity 
of the trials was established through the fidelity of the CDP 
delivery, high rates of treatment adherence, perfect reten-
tion, and through masked outcome assessment. The external 
validity was maximized by eliminating waiting times within 
the TAU group and a 10-month follow-up.
This study had several limitations. First, because the sam-
ple predominantly consisted of female participants, conclu-
sions cannot be made on possible gender differences. How-
ever, considering that the female gender has been identified 
as a risk factor for NSSI, the present sample depicted this 
finding [12]. Furthermore, we were not able to control for 
the naturalistic course of NSSI, because psychotherapeutic 
interventions are adequate and effective in treating NSSI [3]. 
Thus, it would not have been ethically defensible to allow 
participants to wait 10 months before receiving treatment. 
NSSI increases in early adolescence and decreases in late 
adolescence with a peak in mid-adolescence (15–16 years) 
[12]. Because our study sample had a mean age of 14.9 years 
(SD = 1.2) at T0, the frequency of NSSI might also have 
declined due to its natural course. In addition, the assumed 
rate difference between the CDP and TAU groups was rather 
optimistic. However, it should be noted that the group differ-
ence in response rate that we finally found in our trial was 
very small (2.7%); thus, a far larger sample would not have 
led to statistically differences in the main outcome.
In a rigorously conducted RCT, we have shown that CDP 
is not superior to TAU with higher treatment intensity over a 
10-month follow-up for adolescent participants with repeti-
tive NSSI but both treatments were associated with endur-
ing positive outcomes in terms of a significant reduction in 
NSSI frequency, suicide attempts and depression as well as 
a significant improvement in quality of life. In addition, the 
CDP reached faster reductions in NSSI frequency compared 
to TAU. As a conclusion, the CDP showed similar treatment 
outcomes with a faster recovery while requiring less treat-
ment sessions. This study provides important evidence that 
CDP might be an easily accessible, quickly available treat-
ment for patients who would like an alternative to TAU. The 
brevity and potential cost-effectiveness of the CDP alongside 
its non-inferiority may nonetheless justify the implementa-
tion of such a brief psychotherapy manual in existing health 
care systems. As an example, the CDP could complement 
conventional interventions in terms of a stepped-care model 
to provide all concerned persons with easily accessible and 
quick professional help before performing more extensive 
treatments which can then be applied on those who really 
need them.
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